Antiretroviral News and Research

RSS

Guardian examines how Uganda's drought, food shortages affect HIV-positive people

The Guardian examines how "famine and acute food shortages" in Uganda could affect people living with HIV/AIDS. "The situation is beginning to undermine efforts to fight the virus in the north and east of Uganda, the areas most affected by the drought," according to the Guardian.

22 Oct 2009

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing Phase 2a trial of AGS-004, its personalized immunotherapy candidate. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden.

21 Oct 2009

Also in Global Health News: Cholera in Zimbabwe; personal computers; medical 'outliers'; rain in Kenya; generic drugs

A cholera outbreak in Zimbabwe has infected more than 100, resulting in five deaths, state media said Tuesday, Reuters reports, "raising fears of a repeat of last year's epidemic that claimed more than 4,000 lives.

21 Oct 2009

As HIV vaccine conference opens, experts appeal for sustained commitment to global fight against disease

Experts, gathered for the start of a four-day conference on HIV vaccines in Paris, called upon donors to maintain their funding support for the fight against HIV/AIDS despite the global economy, Agence France-Presse reports.

20 Oct 2009

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Merck Frosst Canada Ltd. is pleased to announce that (Pr)ISENTRESS(R) (raltegravir) is now indicated for use in treatment-naïve HIV-1 infected adults in combination with other antiretroviral agents.

20 Oct 2009

GlaxoSmithKline to allow Apotex continue manufacturing their drug in Rwanda

GlaxoSmithKline Inc. (GSK) As part of its broad commitment to improving access to medicines and its ongoing support for Canada's Access to Medicines Regime (CAMR), GlaxoSmithKline confirms it will not object - through CAMR - to allow Canadian company (Apotex) to continue manufacturing their drug for the treatment of HIV/AIDS in Rwanda.

20 Oct 2009

Shire Canada supports initiative for further access to antiretroviral medicine for Rwanda

Shire Canada Inc., a division of Shire plc, announced today its voluntary cooperation to enable further royalty-free access to HIV/AIDS medicines for Rwanda as part of ongoing collaborative efforts to improve health and save lives in the developing world.

20 Oct 2009

IL-2 compound ineffective against HIV-AIDS

An international research team has demonstrated that treating HIV-AIDS with interleukin-2 (IL-2) is ineffective. As a result, the researchers recommend that clinical trials on this compound be stopped.

19 Oct 2009

Novel HIV drug to be studied in cell cultures and patients

A $6 million, five-year federal grant to The Children's Hospital of Philadelphia Research Institute will enable researchers to investigate a novel approach in treating HIV infection---a unique class of drugs focused on developing therapies for psychological and neurological effects in AIDS.

19 Oct 2009

Mothers receiving HAART less likely to transmit HIV virus to their newborns through breastfeeding

Mothers receiving highly active antiretroviral therapy (HAART) to treat HIV-1 infection are less likely than untreated mothers to transmit the virus to their newborns through breastfeeding, according to a new study.

19 Oct 2009

FDA approves 100th antiretroviral for PEPFAR

HHS recently announced the FDA's 100th approval of an antiretroviral drug for PEPFAR, PharmTech.com reports. Seventy-one of the more than 100 drugs reviewed by FDA for PEPFAR were generic products.

19 Oct 2009

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems.

From Ortho-Clinical Diagnostics, Inc. 15 Oct 2009

Opinions: Pragmatic vs. moral approach to health care access; Pres. Bush's PEPFAR

"[T]he global campaign to equalise access to healthcare has had a surprising result: it has made global healthcare more unequal," William Easterly, a professor of economics at New York University and co-director of its Development Research Institute, writes in a Financial Times opinion piece.

15 Oct 2009

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients’ cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.

11 Oct 2009

Recent releases in Global Health

A Lancet comment examines an Affordable Medicines Facility for malaria (AMFm) program to help countries procure subsidized artemisinin-based combination treatments (ACTs).

9 Oct 2009

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy.

9 Oct 2009

Millions of people with HIV/AIDS lack access to lifesaving treatment, says AHF

AIDS Healthcare Foundation (AHF) today hailed the news that four million people from low and middle income countries living with HIV/AIDS were on lifesaving antiretroviral treatment in 2008, a 36% increase over 2007.

9 Oct 2009

CytoDyn to conduct a study on Cytolin at Massachusetts General Hospital

In response to new economic and regulatory realities, CytoDyn, Inc. has made a sea change in its strategy for developing Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS.

9 Oct 2009

AHF criticizes Pfizer for its current pricing of Selzentry AIDS drug

Responding to today’s news that the Food and Drug Administration (FDA) Antiviral Advisory Committee has approved Pfizer Inc.'s AIDS therapy, Selzentry (maraviroc), for use in therapy-naïve patients, AIDS Healthcare Foundation (AHF) strongly criticized Pfizer for its current pricing of the drug at an Average Wholesale Price (AWP) of $13,767 per-patient per-year—which, if this price remains when use is expanded, would make it the most expensive first-line AIDS drug on the market.

9 Oct 2009

Napo Pharmaceuticals hosts educational panel to address global health and environment

Napo Pharmaceuticals, Inc. (Napo) recently hosted an educational panel to address the impact of the lack of access to clean water and enteric disease on global health, the environment, and human rights.

8 Oct 2009

Antiretroviral News and Research

Guardian examines how Uganda's drought, food shortages affect HIV-positive people

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Also in Global Health News: Cholera in Zimbabwe; personal computers; medical 'outliers'; rain in Kenya; generic drugs

As HIV vaccine conference opens, experts appeal for sustained commitment to global fight against disease

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

GlaxoSmithKline to allow Apotex continue manufacturing their drug in Rwanda

Shire Canada supports initiative for further access to antiretroviral medicine for Rwanda

IL-2 compound ineffective against HIV-AIDS

Novel HIV drug to be studied in cell cultures and patients

Mothers receiving HAART less likely to transmit HIV virus to their newborns through breastfeeding

FDA approves 100th antiretroviral for PEPFAR

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

Opinions: Pragmatic vs. moral approach to health care access; Pres. Bush's PEPFAR

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Recent releases in Global Health

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Millions of people with HIV/AIDS lack access to lifesaving treatment, says AHF

CytoDyn to conduct a study on Cytolin at Massachusetts General Hospital

AHF criticizes Pfizer for its current pricing of Selzentry AIDS drug

Napo Pharmaceuticals hosts educational panel to address global health and environment

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News